emedy: Strong Pipeline 2023 and Beyond and transfer to the Main List

Redeye comment on Remedy’s full-year report. Remedy posted an EBIT result in line with our estimated and somewhat higher revenue than expected. Revenue was EUR 19.8 million vs estimated EUR 18.9 million and EBIT was EUR 11.3 million versus our expected EUR 10.7 million.

Länk till analysen i sin helhet: https://www.redeye.se/research/832646/remedy-strong-pipeline-2023-and-beyond-and-transfer-to-the-main-list?utm_source=finwire&utm_medium=RSS